Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 131
- Registration Number
- NCT00783133
A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 440
- Registration Number
- NCT00783263
A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 351
- Registration Number
- NCT00783224
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 728
- Registration Number
- NCT00783146
Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 340
- Registration Number
- NCT00783237
A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 129
- Registration Number
- NCT00783354
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 250
- Registration Number
- NCT00782184
Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 220
- Registration Number
- NCT00780403
Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 189
- Registration Number
- NCT00779532
Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 102
- Registration Number
- NCT00779740
© Copyright 2024. All Rights Reserved by MedPath